BBC NEWS Americas Africa Europe Middle East South Asia Asia Pacific Arabic Spanish Russian Chinese Welsh
BBCi CATEGORIES   TV   RADIO   COMMUNICATE   WHERE I LIVE   INDEX    SEARCH 

BBC NEWS
 You are in:  Business
Front Page 
World 
UK 
UK Politics 
Business 
Market Data 
Economy 
Companies 
E-Commerce 
Your Money 
Business Basics 
Sci/Tech 
Health 
Education 
Entertainment 
Talking Point 
In Depth 
AudioVideo 


Commonwealth Games 2002

BBC Sport

BBC Weather

SERVICES 
Wednesday, 15 May, 2002, 17:07 GMT 18:07 UK
India reforms drug patent laws
Generic drugs
India is the world's largest producer of generic drugs
India's lower house of parliament has approved a bill to reform the country's patent laws, to bring them closer to international standards.


More that 85% of the currently available drugs are going out of patent or are out of patent, therefore India has much go gain from the generic drug industry

Dr Anand Kumar
Astra Zeneca Foundation (India)
The new Patents Second Amendment bill allows the government to license patented drugs to domestic firms in case of public health emergencies when supplies are low or prices too high.

But the bitter pill for India's pharmaceutical industry, which is the biggest generic drug producer in the world, will come if the next part of the bill goes through parliament.

It includes new laws giving full patent protection to drugs, conforming with World Trade Organisation (WTO) obligations to observe international laws from 2005.

Generic headache

Currently, India recognises patents protecting the way a drug is made but not the drug itself, allowing local firms to copy drugs patented in the West as long as they use a different process.

"The minister said the pharma industry needs to come out of its reverse engineering mode and move forward into the research and development mode," Dr Anand Kumar of the Astra Zeneca Foundation in India told the BBC's World Business Report.

"He also said that India is emerging as the new leader for the knowledge based drug industry and that we should protect our interests," he said.

Many global pharmaceutical firms have been holding back investments in India due to the lack of strong patent laws.

Earnings high

Generics are the drug makers main source of revenue because of the cheap labour and research costs and strong exports.

"More that 85% of the currently available drugs are going out of patent or are out of patent, therefore India has much to gain from the generic drug industry," said Dr Kumar.

Analysts expected the strong earnings to continue despite the new laws.

Indian companies have been targeting the lucrative US generic market, where drugs with combined annual sales of about $47bn lose their patent by 2005.

 WATCH/LISTEN
 ON THIS STORY
Dr Anand Kumar, Astra Zeneca Foundation
"Instead of giving the bitter pill in one hit, the government's giving it bit by bit."
See also:

26 Mar 02 | Business
Indian drug firm moves into China
13 Mar 02 | Business
Indian drug maker buys UK firms
Internet links:


The BBC is not responsible for the content of external internet sites

Links to more Business stories are at the foot of the page.


E-mail this story to a friend

Links to more Business stories